The purpose of this clinical trial is to learn if the study treatment Loncastuximab tesirine and Rituximab is safe and efficient before standard of care chimer…

Relapsed or Refractory Large B-cell Lymphoma

~Estimated

~$10 – $6,250

University of UtahNCT06788964

Phase 3

A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractor…

Relapsed or Refractory Large B-cell Lymphoma

~Estimated

~$10 – $7,500

Kite, A Gilead CompanyNCT07479797